Three innovations of next-generation antibiotics: evolvability, specificity, and non-immunogenicity

TL;DR

This paper reviews innovative next-generation antibiotics focusing on specificity, evolvability, and non-immunogenicity, highlighting promising agents like phages and CRISPR, and discusses challenges for clinical adoption to combat antimicrobial resistance.

Contribution

It introduces three key innovations of next-generation antibiotics and discusses potential agents and challenges in bringing them to market.

Findings

Next-generation antibiotics exhibit improved specificity and evolvability.

Potential agents include bacteriophage therapy and CRISPR antimicrobials.

Some agents are currently in clinical development.

Abstract

Antimicrobial resistance is a silent pandemic that is being exacerbated by the uncontrolled use of antibiotics. Since the discovery of penicillin, we have been largely dependent on microbe-derived small molecules to treat bacterial infections. However, the golden era of antibiotics is coming to an end as the emergence and spread of antimicrobial resistance against these antibacterial compounds is outpacing the discovery and development of new antibiotics. The current antibiotic market suffers from various shortcomings, including the absence of profitability and investment. However, the most important underlying issue of traditional antibiotics arises from the inherent properties of these small molecules being mostly broad-spectrum and non-programmable. As the scientific knowledge of microbes progresses, the scientific community is starting to explore entirely novel approaches to tackling antimicrobial resistance. One of the most prominent approaches is to develop next-generation antibiotics. In this review, we discuss three innovations of next-generation antibiotics compared to traditional antibiotics as specificity, evolvability, and non-immunogenicity. We present a number of potential antimicrobial agents, including bacteriophage-based therapy, CRISPR-Cas-based antimicrobials, and microbiome-derived antimicrobial compounds. These alternative antimicrobial agents possess innovative properties that may overcome the inherent shortcomings of traditional antibiotics, and some of these next-generation antibiotics are not merely far-fetched ideas but are currently in clinical development. We further discuss some related issues and challenges such as infection diagnostics and regulatory frameworks that still need to be addressed to bring these next-generation antibiotics to the antibiotic market as viable products to combat antimicrobial resistance using a diversified set of strategies.